The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Subscribe To Our Newsletter & Stay Updated
